G-3 (drug)

Last updated
G-3
3,4-trimethylene-2,5-dimethoxyamphetamine.svg
Clinical data
Other namesG3; Ganesha-3; GANESHA-3; 3C-G-3; 3,4-Trimethylene-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-3,4-(trimethylene)amphetamine; DOG-3
Routes of
administration 		Oral [1]
Drug class Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action 8–12 hours [1]
Identifiers
  • 1-(4,7-dimethoxy-2,3-dihydro-1H-inden-5-yl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
Formula C14H21NO2
Molar mass 235.327 g·mol−1
3D model (JSmol)
  • CC(CC1=CC(=C2CCCC2=C1OC)OC)N
  • InChI=1S/C14H21NO2/c1-9(15)7-10-8-13(16-2)11-5-4-6-12(11)14(10)17-3/h8-9H,4-7,15H2,1-3H3
  • Key:GLFZOKOHBIKEKN-UHFFFAOYSA-N

G-3, also known as 3,4-trimethylene-2,5-dimethoxyamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. [1] [2] [3] It is one of several homologues of Ganesha (G). [1] [2] [3] In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists G-3's dose as 12 to 18 mg orally and its duration as 8 to 12 hours. [1] [2] [3] The effects of G-3 were reported to include closed-eye imagery, no visuals, fantasy, warmth, mellowness, no body disturbance to hints of body discomfort, and "some suggestions of neurological sensitivity". [1] Music was described as not that exciting and it was felt that there could be easy eroticism but there was no push for it. [1] The drug was rated a "plus-three" on the Shulgin Rating Scale despite there "not [being] much of anything" in one report. [1] The chemical synthesis of G-3 has been described. [1] G-3 was first described in the literature by Shulgin in PiHKAL in 1991. [1]

Contents

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN   0-9630096-0-5. OCLC   25627628. https://erowid.org/library/books_online/pihkal/pihkal082.shtml
  2. 1 2 3 Jacob P, Shulgin AT (1994). "Structure-Activity Relationships of the Classic Hallucinogens and Their Analogs". In Lin GC, Glennon RA (eds.). Hallucinogens: An Update (PDF). National Institute on Drug Abuse Research Monograph Series. Vol. 146. National Institute on Drug Abuse. pp. 74–91. PMID   8742795. Archived from the original on 13 July 2025.
  3. 1 2 3 Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN   978-0-12-433951-4. Archived from the original on 13 July 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.